ArticleCell death discovery2026
Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard treatment for advanced ovarian cancer involves initial surgery followed by platinum-based chemotherapy. Although most patients are sensitive, most relapses occur at a later stage, highlighting the urgent need to understand the tumour microenvironment following neoadjuvant chemotherapy (NACT). To explore the mechanisms underlying chemotherapy resistance, we analysed published single-cell RNA sequencing (scRNA-seq) data from patients with high-grade serous ovarian cancer and performed several in vitro and in vivo experiments to investigate the role of prostaglandins in immunosuppressive microenvironment formation. Prostaglandin-mediated immunosuppressive microenvironment formation was a critical contributor to chemotherapy resistance following cisplatin treatment. Mechanistically, cisplatin-treated ovarian cancer cells induced the formation of myeloid-derived suppressor cells (MDSCs), which inhibited the cytotoxicity of CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.